Trials / Withdrawn
WithdrawnNCT02762448
Interferon-free Antiviral Treatment of HCV-Positive Genotype 1b Related Indolent Non-Hodgkin Lymphomas
Interferon-free Antiviral Treatment of HCV-Positive Genotype 1b Related Indolent Non-Hodgkin Lymphomas Patients Using Daclatasvir and Asunaprevir: A Pilot Study
- Status
- Withdrawn
- Phase
- —
- Study type
- Observational
- Enrollment
- 0 (actual)
- Sponsor
- Tainan Municipal Hospital · Academic / Other
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
Interferon-free Antiviral Treatment of HCV-Positive Genotype 1b Related Indolent non-Hodgkin Lymphomas Patients Using Daclatasvir and Asunaprevir: A Pilot Study
Detailed description
Prospectively collect cases with NHL (n=10), having HCV genotype 1b related NHL, who will be treated with ASV (200 mg twice daily) + DCV(60 mg once daily) for 24 weeks The patients will be observed and followed to determine whether there is regression of NHL after antiviral treatment. Conventional chemotherapy should be initiated shortly in cases without regression.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Daclatasvir+ Asunaprevir | HCV clearance and complete regression of NHL by ASV+ DCV |
Timeline
- Start date
- 2016-07-01
- Primary completion
- 2018-01-01
- Completion
- 2018-04-18
- First posted
- 2016-05-05
- Last updated
- 2018-04-19
Source: ClinicalTrials.gov record NCT02762448. Inclusion in this directory is not an endorsement.